Lack of Stroke Subtype Information May Hinder Indirect Comparison Between the ROCKET-AF and Other Trials of New Oral Anticoagulants

Although we agree with Lip et al. () on the limitation of their study, we argue that lack of stroke subtype information may hinder scientific conclusion by including the ROCKET-AF (Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) in any indirect comparison of new oral anticoagulants (NOA).

http://www.jaccjournaloftheacc.com/article/PIIS0735109712055477/abstract?rss=yes

Source: Journal of the American College of Cardiology - January 30, 2013 Category: Cardiology Authors: Hai-feng Li, Ren-liang Zhao Tags: Letters to the Editor Source Type: research